Drug Profile
ONO AE 248
Latest Information Update: 22 Aug 2002
Price :
$50
*
At a glance
- Originator Ono Pharmaceutical
- Class Anti-ischaemics; Prostaglandins
- Mechanism of Action Potassium channel agonists; Prostaglandin E3 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Reperfusion injury
Most Recent Events
- 25 Jun 1998 New profile
- 25 Jun 1998 Preclinical development for Reperfusion injury in Japan (Unknown route)
- 25 Jun 1998 Preclinical development for Reperfusion injury in United Kingdom (Unknown route)